With a longer follow-up, the number of patients enrolled in this trial was increased, and 62 R/R MM patients received the combined infusion of anti-BCMA and anti-CD19 CAR-T cells (26, 27). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.